Severe cutaneous adverse reactions to antiepileptic drugs in Asians

Neurology

Volumn 77, Issue 23, 2011, Pages 2025-2033

  Yang, C Y ^a   Dao, R L ^a   Lee, T J ^b   Lu, C W ^a,c   Yang, C H ^a   Hung, S I ^d   Chung, Wen Hung ^a,b  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c TZU CHI UNIVERSITY   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMAZEPINE; CLONAZEPAM; CORTICOSTEROID; ETIRACETAM; GABAPENTIN; IMMUNOGLOBULIN G; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ADULT; ARTICLE; ASIAN; CONTROLLED STUDY; DISEASE SEVERITY; DRESS SYNDROME; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; SEIZURE; SEVERE CUTANEOUS ADVERSE DRUG REACTION; SKIN MANIFESTATION; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 82955243735     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31823b478c     Document Type: Article

References (33)

1. Roujeau JC, Kelly JP, Naldi L, et al. Medication use andthe risk of Stevens-Johnson syndrome or toxic epidermalnecrolysis. N Engl J Med 1995;333:1600-1607.
2. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, SternR. Risk of Stevens-Johnson syndrome and toxic epidermalnecrolysis during first weeks of antiepileptic therapy: Acase-control study: Study Group of the International CaseControl Study on Severe Cutaneous Adverse Reactions.Lancet 1999;353:2190-2194.
3. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L,Roujeau JC. Clinical classification of cases of toxic epidermalnecrolysis, Stevens-Johnson syndrome, and erythemamultiforme. Arch Dermatol 1993;129:92-96. (Pubitemid 23029676)
4. Chan HL, Stern RS, Arndt KA, et al. The incidence oferythema multiforme, Stevens-Johnson syndrome, andtoxic epidermal necrolysis: A population-based study withparticular reference to reactions caused by drugs amongoutpatients. Arch Dermatol 1990;126:43-47. (Pubitemid 20040979)
5. Di Pascuale MA, Espana EM, Liu DT, et al. Correlation ofcorneal complications with eyelid cicatricial pathologies inpatients with Stevens-Johnson syndrome and toxic epidermalnecrolysis syndrome. Ophthalmology 2005;112:904-912. (Pubitemid 40631513)
6. Mockenhaupt M, Messenheimer J, Tennis P, SchlingmannJ. Risk of Stevens-Johnson syndrome and toxic epidermalnecrolysis in new users of antiepileptics. Neurology2005;64:1134-1138.
7. Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivitysyndrome: Incidence, prevention and management.Drug Saf 1999;21:489-501. (Pubitemid 30021105)
8. Chiou CC, Yang LC, Hung SI, et al. Clinicopathologicalfeatures and prognosis of drug rash with eosinophilia andsystemic symptoms: A study of 30 cases in Taiwan. J EurAcad Dermatol Venereol 2008;22:1044-1049.
9. Roujeau JC, Stern RS. Severe adverse cutaneous reactionsto drugs. N Engl J Med 1994;331:1272-1285. (Pubitemid 24333193)
10. Chung WH, Hung SI, Hong HS, et al. Medical genetics: Amarker for Stevens-Johnson syndrome. Nature 2004;428:486.
11. Chung WH, Hung SI. Genetic markers and danger signalsin Stevens-Johnson syndrome and toxic epidermal necrolysis.Allergol Int 2010;59:325-332.
12. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, et al. Variabilityin the clinical pattern of cutaneous side-effects ofdrugs with systemic symptoms: Does a DRESS syndromereally exist? Br J Dermatol 2007;156:609-611.
13. Naranjo CA, Busto U, Sellers EM, et al. A method forestimating the probability of adverse drug reactions. ClinPharmacol Ther 1981;30:239-245. (Pubitemid 12149145)
14. Sassolas B, Haddad C, Mockenhaupt M, et al. ALDEN, analgorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: Comparisonwith case-control analysis. Clin Pharmacol Ther2010;88:60-68.
15. Lin MS, Dai YS, Pwu RF, Chen YH, Chang NC. Riskestimates for drugs suspected of being associated withStevens-Johnson syndrome and toxic epidermal necrolysis:A case-control study. Intern Med J 2005;35:188-190.
16. Farkas R. Adverse events of carbamazepine. Available at:www.accessdata. fda.gov/drugsatfda-docs/nda/2007/016608s098,020712s029,021710-ClinRev.pdf. Accessed October26, 2007.
17. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome: Ethnicity matters. PharmacogenomicsJ 2006;6:265-268. (Pubitemid 44137953)
18. Hsieh LP, Huang CY. Antiepileptic drug utilization inTaiwan: Analysis of prescription using National Health Insurancedatabase. Epilepsy Res 2009;84:21-27.
19. Griffeth LK, Rosen GM, Rauckman EJ. Effects of modeltraumatic injury on hepatic drug metabolism in the rat: V:sulfation and acetylation. Drug Metab Dispos 1985;13:398-405. (Pubitemid 15237520)
20. Hirsch LJ, Weintraub DB, Buchsbaum R, et al. Predictors oflamotrigine-associated rash. Epilepsia 2006;47: 318-322.
21. Gau SS, Chao PF, Lin YJ, Chang CJ, Gau CS. The associationbetween carbamazepine and valproate and adversecutaneous drug reactions in patients with bipolar disorder:A nested matched case-control study. J Clin Psychopharmacol2008;28:509-517.
22. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessmentof medication risks with emphasis on recentlymarketed drugs: The EuroSCAR study. J Invest Dermatol2008;128:35-44. (Pubitemid 350249390)
23. Roujeau JC. Clinical heterogeneity of drug hypersensitivity.Toxicology 2005;209:123-129.
24. Wolf R, Orion E, Marcos B, Matz H. Life-threateningacute adverse cutaneous drug reactions. Clin Dermatol2005;23:171-181. (Pubitemid 40410720)
25. Angle P, Thomas P, Chiu B, Freedman J. Bronchiolitisobliterans with organizing pneumonia and cold agglutinindisease associated with phenytoin hypersensitivity syndrome.Chest 1997;112:1697-1699. (Pubitemid 28007787)
26. Blondin NA, Zahedi S, Hale MS. A case of lamotrigineassociatedanticonvulsant hypersensitivity syndrome.Prim Care Companion. J Clin Psychiatry 2008;10:249-250.
27. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, MuraineM. Risk factors for the development of ocularcomplications of Stevens-Johnson syndrome and toxicepidermal necrolysis. Arch Dermatol 2009;145:157-162.
28. Mittmann N, Chan B, Knowles S, Cosentino L, Shear N.Intravenous immunoglobulin use in patients with toxicepidermal necrolysis and Stevens-Johnson syndrome. Am JClin Dermatol 2006;7:359-368. (Pubitemid 46998570)
29. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC,Mockenhaupt M. Effects of treatments on the mortality ofStevens-Johnson syndrome and toxic epidermal necrolysis:A retrospective study on patients included in the prospectiveEuroSCAR Study. J Am Acad Dermatol 2008;58:33-40. (Pubitemid 350298143)
30. Chung WH, Hung SI, Yang JY, et al. Granulysin is a keymediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. NatMed 2008;14:1343-1350.
31. Ghislain PD, Roujeau JC. Treatment of severe drug reactions:Stevens- Johnson syndrome, toxic epidermal necrolysisand hypersensitivity syndrome. Dermatol Online J2002;8:5.
32. Hirsch LJ, Arif H, Nahm EA, Buchsbaum R, Resor SR Jr,Bazil CW. Cross-sensitivity of skin rashes with antiepilepticdrug use. Neurology 2008;71:1527-1534.
33. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity patternof rash from current aromatic antiepileptic drugs. EpilepsyRes 2008;80:194-200.